登录
 机构网站
  1. 首页
  2. 情报产品
  3. 快讯详情

《BioRxiv，3月15日，Structural and functional conservation of the programmed -1 ribosomal frameshift signal of SARS-CoV-2》

  • 来源专题：COVID-19科研动态监测
  • 编译者： zhangmin
  • 发布时间：2020-03-16

  • Structural and functional conservation of the programmed -1 ribosomal frameshift signal of SARS-CoV-2

    Jamie A. Kelly, Jonathan D. Dinman

    doi: https://doi.org/10.1101/2020.03.13.991083

    Abstract

    17 years after the SARS-CoV epidemic, the world is facing the COVID-19 pandemic. COVID-19 is caused by a coronavirus named SARS-CoV-2. Given the most optimistic projections estimating that it will take more than a year to develop a vaccine, our best short term strategy may lie in identifying virus-specific targets for small molecule interventions. All coronaviruses utilize a molecular mechanism called -1 PRF to control the relative expression of their proteins. Prior analyses of SARS-CoV revealed that it utilizes a structurally unique three-stemmed mRNA pseudoknot to stimulate high rates of -1 PRF, that it also harbors a -1 PRF attenuation element.

    *注，本文为预印本论文手稿，是未经同行评审的初步报告，其观点仅供科研同行交流，并不是结论性内容，请使用者谨慎使用.

  • 原文来源：https://www.biorxiv.org/content/10.1101/2020.03.13.991083v1
9浏览量
原文链接
相关报告

  • 《3月15日_SARS-CoV-2程序性-1核糖体移码信号的结构和功能保守》
    • 来源专题：COVID-19科研动态监测
    • 编译者：zhangmin
    • 发布时间：2020-03-17
    • 1.时间：2020年3月15日 2.机构或团队：美国马里兰大学 3.事件概要： bioRxiv预印平台于3月15日发布了美国马里兰大学的论文“Structural and functional conservation of the programmed -1 ribosomal frameshift signal of SARS-CoV-2”。 文章称，根据最乐观的预测，估计将需要一年以上的时间来开发COVID-19疫苗，最好的短期策略可能在于识别小分子干预措施的病毒特异性靶标。所有冠状病毒均利用一种称为-1 PRF（programmed -1 ribosomal frameshift，程序性-1核糖体移码信号）的分子机制来控制其蛋白的相对表达。先前对SARS-CoV的分析表明其利用结构独特的具有三茎环mRNA假结来刺激-1 PRF的高比率，并且它还带有-1 PRF衰减元件。-1 PRF活性的改变会对病毒复制产生负面影响，表明该分子机制具有潜在的治疗性靶向。 该研究中，研究人员对SARS-CoV和SARS-CoV-2移码信号进行比较分析。结构分析表明，由U UUA AAC滑脱位点和三茎环mRNA假结组成的核心-1 PRF信号高度保守。相反，上游衰减器发夹结构的保守性较差。功能测定表明，这两种元件都促进了-1 PRF的相似比率，并且在滑脱位中的沉默编码突变强烈消除了-1 PRF的活性。研究人员建议，以前被鉴定为抑制SARS-CoV介导的-1 PRF的分子可能作为抵抗当前大流行的先导化合物。 *注，本文为预印本论文手稿，是未经同行评审的初步报告，其观点仅供科研同行交流，并不是结论性内容，请使用者谨慎使用。 4.附件： 原文链接：https://www.biorxiv.org/content/10.1101/2020.03.13.991083v1
    203浏览量
    原文链接

  • 《bioRxiv，4月3日，SARS-CoV-2 neutralizing serum antibodies in cats: a serological investigation》
    • 来源专题：COVID-19科研动态监测
    • 编译者：xuwenwhlib
    • 发布时间：2020-04-05
    • SARS-CoV-2 neutralizing serum antibodies in cats: a serological investigation Qiang Zhang, Huajun Zhang, Kun Huang, Yong Yang, Xianfeng Hui, Jindong Gao, Xinglin He, Chengfei Li, Wenxiao Gong, Yufei Zhang, Cheng Peng, Xiaoxiao Gao, Huanchun Chen, Zhong Zou, Zhengli Shi, Meilin Jin doi: https://doi.org/10.1101/2020.04.01.021196 Abstract Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was first reported in Wuhan, China, and rapidly spread worldwide. Previous studies suggested cat could be a potential susceptible animal of SARS-CoV-2. Here, we investigated the infection of SARS-CoV-2 in cats by detecting specific serum antibodies. A cohort of serum samples were collected from cats in Wuhan, including 102 sampled after COVID-19 outbreak, and 39 prior to the outbreak. 15 of 102 (14.7%) cat sera collected after the outbreak were positive for the receptor binding domain (RBD) of SARS-CoV-2 by indirect enzyme linked immunosorbent assay (ELISA). Among the positive samples, 11 had SARS-CoV-2 neutralizing antibodies with a titer ranging from 1/20 to 1/1080. No serological cross-reactivity was detected between the SARS-CoV-2 and type I or II feline infectious peritonitis virus (FIPV). Our data demonstrates that SARS-CoV-2 has infected cat population in Wuhan during the outbreak. *注，本文为预印本论文手稿，是未经同行评审的初步报告，其观点仅供科研同行交流，并不是结论性内容，请使用者谨慎使用.
    49浏览量
    原文链接